Skip to main content

Table 3 HPV prevalence detected by Cervista and HC2 in comparison to LBC

From: A population-based observational study comparing Cervista and Hybrid Capture 2 methods: improved relative specificity of the Cervista assay by increasing its cut-off

LBC

CER+ve (%)

HR HC2+ve (%)

κ (95% CI)

Normal (Pap I/II)

10.8%

5.7%

0.53 (0.43-0.61)

ASC-US (Pap IIw)

30.8%

27.7%

0.55 (0.33-0.78)

ASC-H, AGUS (Pap III)

50.0%

45.0%

0.9 (0.71-1.0)

LSIL, HSIL (Pap IIID)

67.2%

71.5%

0.82 (0.75-0.88)

HSIL, CIS (Pap IVa)

97.2%

100 %

1

HSIL, CIS, Micro (IVb)

100%

100%

1

Microinvasive (Pap V)

100%

100%

1

AGUS+ (≥Pap III)

71.3%

75.2%

0.83 (0.77-0.88)

HSIL+ (≥Pap IVa)

100%

100%

1

Total

27.8%

25.2%

0.8 (0.77-0.84)

  1. +ve: positive; +: and higher.
  2. 95% CI for HPV prevalence were calculated using the Wilson Score method.